PMID 18754850 Red ginseng for treating erectile dysfunction: a systematic review 메타분석 · Br J Clin Pharmacol, 2008 7개 RCT - 홍삼이 위약유효 성분이 없는 가짜 약(플라시보). 효과 비교의 기준으로 쓴다.보다 나은 발기부전 반응(6개 시험 349명, RR 2.40). 단, 시험의 질·규모가 낮아 확정적 결론은 유보.
핵심요약
홍삼(찌기 전 껍질을 벗기지 않은 인삼을 쪄서 말린 것)의 발기부전 효과를 평가한 체계적 문헌고찰. 언어 제한 없이 20개 데이터베이스를 검색해 7개 RCT를 포함했고, 이 중 위약유효 성분이 없는 가짜 약(플라시보). 효과 비교의 기준으로 쓴다. 대조 6개 시험(349명)의 메타분석여러 개별 연구의 결과를 통계적으로 합쳐 하나의 종합 결론을 내는 분석.에서 홍삼군의 반응 위험비가 2.40(95% CI 1.65~3.51, I²=22%)으로 유의했다. 심인성 발기부전 하위분석에서도 유익했다(RR 2.05). 다만 시험의 방법론적 질이 평균적으로 낮고 표본과 시험 수가 적어, 저자들은 확정적 결론을 내리기엔 부족하며 더 엄격한 연구가 필요하다고 밝혔다.
원문 초록 보기
AIMS: Korean red ginseng (unskinned Panax ginseng before it is steamed or otherwise heated and subsequently dried) is one of the most widely used herbal remedies. This systematic review evaluates the current evidence for the effectiveness of red ginseng for treating erectile dysfunction. METHODS: Systematic searches were conducted on 20 electronic databases without language restrictions. Hand-searches included conference proceedings and our files. All randomized clinical studies (RCT) of red ginseng as a treatment of erectile dysfunction were considered for inclusion. Methodological quality was assessed using the Jadad score. RESULTS: Seven RCTs met all the inclusion criteria. Their methodological quality was low on average. Six of the included RCTs compared the therapeutic efficacy of red ginseng with placebo. The meta-analysis of these data showed a significant effect (n = 349, risk ratio, 2.40; 95% CI of 1.65, 3.51, p < 0.00001, heterogeneity: tau(2) = 0.05, chi(2) = 6.42, p = 0.27, I(2) = 22%). Subgroup analyses also showed beneficial effects of red ginseng in psychogenic erectile dysfunction (n = 135, risk ratio, 2.05; 95% CI of 1.33, 3.16, p = 0.001, heterogeneity: chi(2) = 0.08, p = 0.96, I(2) = 0%). CONCLUSIONS: Collectively these RCTs provide suggestive evidence for the effectiveness of red ginseng in the treatment of erectile dysfunction. However, the total number of RCTs included in the analysis, the total sample size and the methodological quality of the primary studies were too low to draw definitive conclusions. Thus more rigorous studies are necessary. ※ 파이프라인이 API로 수집·저장한 초록 원문 그대로. 한국어 핵심요약은 이 텍스트만을 근거로 작성됩니다.
원문 보기 ↗ PMID 35776997 Efficacy of ginseng supplements on disease-related fatigue: A systematic review and meta-analysis 메타분석 · Medicine (Baltimore), 2022 12개 RCT·1,298명 - 인삼 보충이 질환 관련 피로를 유의하게 줄임(표준화 평균차 0.33).
핵심요약
질환을 가진 성인의 피로에 대한 인삼 보충 효과를 종합한 메타분석여러 개별 연구의 결과를 통계적으로 합쳐 하나의 종합 결론을 내는 분석.(12개 RCT, 1,298명). 고정효과 분석에서 인삼 보충은 질환 관련 피로를 유의하게 줄였다(표준화 평균차 0.33). 저자들은 인삼 보충이 환자의 질환 관련 피로를 줄이는 데 도움이 된다고 결론지었다. 다만 인삼속을 폭넓게 포함해 홍삼 단독의 기여를 분리하기 어렵고, 아래 더 큰 메타분석과 결과가 엇갈린다는 점을 함께 봐야 한다.
원문 초록 보기
BACKGROUND: Ginseng has been believed to provide energy, physical health, and well-being to patients for hundreds of years. Fatigue is a multidimensional symptom with unknown etiology and varying severity, and lots of patients suffer from fatigue. METHODS: We search for research of ginseng treatment of disease-related fatigue in adult patients in Pubmed, Embase, Medline, and Cochrane library. Two independent reviewers assessed included studies and met to develop consensus on included studies. And we used Review Manager 5.3 software to evaluate the risk of bias. RESULTS: The present meta-analysis included 12 randomized controlled trial containing 1298 patients. In the fixed-effect meta-analysis of 12 randomized controlled trial, ginseng supplements had a statistically significant efficacy on disease-related fatigue reduction (standardized mean difference = 0.33, 95% confidence interval = 0.44-0.22). CONCLUSIONS: The use of ginseng supplements is benefit for patients to reduce disease-related fatigue. ※ 파이프라인이 API로 수집·저장한 초록 원문 그대로. 한국어 핵심요약은 이 텍스트만을 근거로 작성됩니다.
원문 보기 ↗ PMID 36730693 Ginseng and Ginseng Herbal Formulas for Symptomatic Management of Fatigue: A Systematic Review and Meta-Analysis 메타분석 · J Integr Complement Med, 2023 19개 RCT - 전체적으로는 피로 감소가 유의하지 않음(SMD -0.36). 복합처방·만성피로·일반 피로 하위군에서만 유의, 효과 크기 모두 작음.
핵심요약
인삼과 인삼 복합처방의 피로 관리 효과를 종합한 메타분석여러 개별 연구의 결과를 통계적으로 합쳐 하나의 종합 결론을 내는 분석.(19개 RCT, MSKCC 통합의학팀). 전체 통합 분석에서는 피로 심각도 감소가 유의하지 않았다(SMD -0.36, 95% CI -0.82~0.11, P=0.13). 하위분석에서 인삼 복합처방(SMD -0.39)과 만성피로(-0.30), 일반(비질환) 피로(-0.48)에서만 유의했고, 효과 크기는 모두 작았다. 삶의 질은 개선 경향(P=0.05)을 보였고 부작용은 대조군보다 늘지 않았다. 저자들은 표준 사용법에 대한 지침과 엄격한 RCT가 더 필요하다고 밝혔다.
원문 초록 보기
Objectives: Ginseng has been widely used in fatigue management. However, its efficacy on fatigue remains unclear. This study aimed to assess the efficacy and safety of ginseng and ginseng herbal formulas for fatigue in randomized clinical trials (RCTs). Methods: The authors searched PubMed, Embase, Cochrane, Web of Science, and Allied and Complementary Medicine Database (AMED) databases from inception to July 6, 2022. Outcomes included fatigue severity, quality of life (QoL), and adverse events (AEs). Quality of evidence was assessed using the Cochrane Risk of Bias Tool. They pooled all included data and performed subgroup analysis by fatigue type, assessment instrument, and ginseng type. Results: The authors included 19 RCTs. Pooled analyses found no significant reduction in fatigue severity with ginseng versus controls (standardized mean difference [SMD]: -0.36, 95% confidence interval [CI]: -0.82 to 0.11, p = 0.13). In subgroup analysis, there was significant fatigue reduction with the ginseng herbal formula (SMD: -0.39, 95% CI: -0.66 to -0.13, p = 0.004) and chronic fatigue (CF) (SMD: -0.30, 95% CI: -0.56 to -0.03, p = 0.03) compared to controls. Ginseng produced significant reductions in general (i.e., non-disease-specific) fatigue compared to controls (SMD: -0.48, 95% CI: -0.71 to -0.25, p < 0.0001). Ginseng was associated with a trend toward QoL improvement (p = 0.05) and did not increase AEs compared with controls. Effect sizes were small. Conclusion: Ginseng herbal formulas improved fatigue severity compared to controls, especially among patients with CF, but with a small effect size. Rigorous RCTs as well as guidelines for standard ginseng usage are needed to further evaluate the effects of ginseng for fatigue and ensure proper use. ※ 파이프라인이 API로 수집·저장한 초록 원문 그대로. 한국어 핵심요약은 이 텍스트만을 근거로 작성됩니다.
원문 보기 ↗ PMID 25265315 The effect of ginseng (the genus panax) on glycemic control: a systematic review and meta-analysis of randomized controlled clinical trials 메타분석 · PLoS One, 2014 16개 RCT - 인삼이 공복혈당을 소폭 낮춤(-0.31 mmol/L). 공복 인슐린·HbA1c·HOMA-IR에는 유의한 전체 효과 없음.
핵심요약
당뇨 유무와 관계없이 인삼의 혈당 조절 효과를 종합한 메타분석여러 개별 연구의 결과를 통계적으로 합쳐 하나의 종합 결론을 내는 분석.(16개 RCT, 30일 이상). 인삼은 대조군 대비 공복혈당을 유의하게 낮췄으나 폭은 작았다(평균차 -0.31 mmol/L, 95% CI -0.59~-0.03). 공복 인슐린·당화혈색소지난 2~3개월 평균 혈당을 반영하는 혈액 지표(HbA1c). 당뇨 조절 정도를 본다.·HOMA-IR에는 유의한 전체 효과가 없었고, HbA1c는 평행설계 대 교차설계 하위분석에서만 감소했다(-0.22%). 대부분 12주 미만으로 짧고 참가자의 기저 혈당 조절이 양호했다. 저자들은 표준화된 제제로 더 크고 긴 시험이 필요하다고 결론지었다.
원문 초록 보기
IMPORTANCE: Despite the widespread use of ginseng in the management of diabetes, supporting evidence of its anti-hyperglycemic efficacy is limited, necessitating the need for evidence-based recommendations for the potential inclusion of ginseng in diabetes management. OBJECTIVE: To elucidate the effect of ginseng on glycemic control in a systematic review and meta-analysis of randomized controlled trials in people with and without diabetes. DATA SOURCES: MEDLINE, EMBASE, CINAHL and the Cochrane Library (through July 3, 2013). STUDY SELECTION: Randomized controlled trials ≥30 days assessing the glycemic effects of ginseng in people with and without diabetes. DATA EXTRACTION: Relevant data were extracted by 2 independent reviewers. Discrepancies were resolved by consensus. The Heyland Methodological Quality Score and the Cochrane risk of bias tool were used to assess study quality and risk of bias respectively. DATA SYNTHESIS: Sixteen trials were included, in which 16 fasting blood glucose (n = 770), 10 fasting plasma insulin (n = 349), 9 glycated hemoglobin (n = 264), and 7 homeostasis model assessment of insulin resistance (n = 305) comparisons were reported. Ginseng significantly reduced fasting blood glucose compared to control (MD = -0.31 mmol/L [95% CI: -0.59 to -0.03], P = 0.03). Although there was no significant effect on fasting plasma insulin, glycated hemoglobin, or homeostasis model assessment of insulin resistance, a priori subgroup analyses did show significant reductions in glycated hemoglobin in parallel compared to crossover trials (MD = 0.22% [95%CI: 0.06 to 0.37], P = 0.01). LIMITATIONS: Most trials were of short duration (67% trials<12wks), and included participants with a relatively good glycemic control (median HbA1c non-diabetes = 5.4% [2 trials]; median HbA1c diabetes = 7.1% [7 trials]). CONCLUSIONS: Ginseng modestly yet significantly improved fasting blood glucose in people with and without diabetes. In order to address the uncertainty in our effect estimates and provide better assessments of ginseng's anti-diabetic efficacy, larger and longer randomized controlled trials using standardized ginseng preparations are warranted. TRIAL REGISTRATION: ClinicalTrials.gov NCT01841229. ※ 파이프라인이 API로 수집·저장한 초록 원문 그대로. 한국어 핵심요약은 이 텍스트만을 근거로 작성됩니다.
원문 보기 ↗ PMID 27074879 The effect of ginseng (genus Panax) on blood pressure: a systematic review and meta-analysis of randomized controlled clinical trials 메타분석 · J Hum Hypertens, 2016 17개 RCT·1,381명 - 인삼이 수축기·이완기·평균동맥압에 유의한 영향 없음. '혈압을 올린다'는 우려로 사용을 말릴 이유는 없다고 결론.
핵심요약
반복 복용 시 인삼이 혈압에 미치는 영향을 종합한 메타분석여러 개별 연구의 결과를 통계적으로 합쳐 하나의 종합 결론을 내는 분석.(17개 시험, 1,381명, 4주 이상). 인삼은 수축기·이완기·평균동맥압 어디에도 유의한 영향을 주지 않았다. 당뇨·대사증후군·비만 하위군에서 수축기 혈압이 낮아지는 경향이 있었으나 유의하지 않았고(평균 -2.76 mmHg, P=0.14), 체질량지수와 치료 효과 사이에는 유의한 연관이 있었다(β=-0.95, P=0.007). 저자들은 인삼이 혈관에 중립적으로 보이므로 혈압 상승 우려로 사용을 말릴 이유는 없다고 결론지었다.
원문 초록 보기
Pre-clinical evidence indicates the potential for ginseng to reduce cardiovascular disease risk and acutely aid in blood pressure (BP) control. Clinical evidence evaluating repeated ginseng exposure, however, is controversial, triggering consumer and clinician concern. A systematic review and meta-analysis were conducted to assess whether ginseng has an effect on BP. MEDLINE, EMBASE, Cochrane and CINAHL were searched for relevant randomized controlled trials ⩾4 weeks that compared the effect of ginseng on systolic (SBP), diastolic (DBP) and/or mean arterial (MAP) BPs to control. Two independent reviewers extracted data and assessed methodological quality and risk of bias. Data were pooled using random-effects models and expressed as mean differences (MD) with 95% confidence intervals (CIs). Heterogeneity was assessed and quantified. Seventeen studies satisfied eligibility criteria (n=1381). No significant effect of ginseng on SBP, DBP and MAP was found. Stratified analysis, although not significant, appears to favour systolic BP improvement in diabetes, metabolic syndrome and obesity (MD=-2.76 mm Hg (95% CI=-6.40, 0.87); P=0.14). A priori subgroup analyses revealed significant association between body mass index and treatment differences (β=-0.95 mm Hg (95% CI=-1.56, -0.34); P=0.007). Ginseng appears to have neutral vascular affects; therefore, should not be discouraged for concern of increased BP. More high-quality, randomized, controlled trials assessing BP as a primary end point, and use of standardized ginseng root or extracts are warranted to limit evidence of heterogeneity in ginseng research and to better understand its cardiovascular health potential. ※ 파이프라인이 API로 수집·저장한 초록 원문 그대로. 한국어 핵심요약은 이 텍스트만을 근거로 작성됩니다.
원문 보기 ↗ PMID 19592479 North American (Panax quinquefolius) and Asian Ginseng (Panax ginseng) Preparations for Prevention of the Common Cold in Healthy Adults: A Systematic Review 체계적 문헌고찰 · Evid Based Complement Alternat Med, 2011 5개 시험·747명 - 포함된 시험이 모두 북미인삼. 감기 발생·중증도 감소는 근거 불충분, 지속 기간은 약 6.2일 단축.
핵심요약
건강한 성인에서 인삼 제제의 감기 예방 효과를 평가한 체계적 문헌고찰(5개 시험, 747명). 중요한 점은 포함된 다섯 시험이 모두 북미인삼(Panax quinquefolius)을 대상으로 했다는 것이다. 감기 총 횟수는 한 시험에서 25% 감소했고 감기·급성호흡기감염 지속 기간은 두 시험에서 약 6.2일 단축됐다. 그러나 감기에 한 번이라도 걸릴 위험은 유의하게 줄지 않았다(RR 0.70, 95% CI 0.48~1.02). 저자들은 인삼이 감기의 발생이나 중증도를 줄인다고 결론짓기엔 근거가 불충분하다고 밝혔다. 홍삼(아시아 인삼) 자체의 근거는 이 고찰에 포함되지 않았다.
원문 초록 보기
BACKGROUND: Standardized ginseng extract has become the best-selling cold and flu remedy in Canada, yet much controversy regarding the efficacy of ginseng in preventing common colds remains. OBJECTIVE: To assess the efficacy of ginseng preparations for the prevention of common colds in healthy adults. METHODS: Comprehensive bibliographic database, trial registry and grey literature searches were conducted up to December 2007. Randomized controlled trials or controlled clinical trials comparing North American (Panax quinquefolius) or Asian ginseng (Panax ginseng) root extract to placebo or no treatment in healthy adults were included. Two reviewers independently applied the study selection criteria and assessed methodological quality. RESULTS: Five trials involving 747 participants were included. All five trials examined North American ginseng. The methodological quality of the trials varied widely. Ginseng preparations significantly reduced the total number of common colds by 25% compared to placebo (one trial; 95% CI: 5-45). There was a tendency toward a lower incidence of having at least one common cold or other acute respiratory infection (ARI) in the ginseng group compared to the placebo group (five trials; relative risk: 0.70; 95% CI: 0.48-1.02). Compared to placebo, ginseng significantly shortened the duration of colds or ARIs by 6.2 days (two trials; 95% CI: 3.4-9.0). CONCLUSIONS: There is insufficient evidence to conclude that ginseng reduces the incidence or severity of common colds. North American ginseng appears to be effective in shortening the duration of colds or ARIs in healthy adults when taken preventatively for durations of 8-16 weeks. ※ 파이프라인이 API로 수집·저장한 초록 원문 그대로. 한국어 핵심요약은 이 텍스트만을 근거로 작성됩니다.
원문 보기 ↗ 